Telomir Pharmaceuticals Inc
NASDAQ:TELO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hunan Junxin Environmental Protection Co Ltd
SZSE:301109
|
CN |
Telomir Pharmaceuticals Inc
Other Current Liabilities
Telomir Pharmaceuticals Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Telomir Pharmaceuticals Inc
NASDAQ:TELO
|
Other Current Liabilities
$473.8k
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$1.4B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$4.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$25B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$8.5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Telomir Pharmaceuticals Inc
Glance View
Telomir Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2024-02-09. Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The firm is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.
See Also
What is Telomir Pharmaceuticals Inc's Other Current Liabilities?
Other Current Liabilities
473.8k
USD
Based on the financial report for Dec 31, 2025, Telomir Pharmaceuticals Inc's Other Current Liabilities amounts to 473.8k USD.
What is Telomir Pharmaceuticals Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
-7%
Over the last year, the Other Current Liabilities growth was 407%. The average annual Other Current Liabilities growth rates for Telomir Pharmaceuticals Inc have been -7% over the past three years .
